Schrodinger
SDGR
22.93
-3.41
-12.95%
Schrodinger
US · SDGR
#2667 by market cap
Listed 2020
22.93
-3.41
-12.95%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 30 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.5 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 103.13% -0.54pp
- Institutions
- 317 +30
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund59.23%
Foundation21.51%
Hedge Fund15.84%
Public Company3.31%
Individual/Insider2.52%
Private Company1.55%
Government Pension Fund0.89%
Insurance Company0.60%
Family Office/Trust0.15%
Other0.82%
Top holders as of 2026-06-30
Bill & Melinda Gates Foundation Asset Trust
21.51% · 16.15M sh
BlackRock
13.71% · 10.29M sh
Rubric Capital Management LP
8.52% · 6.40M sh
Vanguard Portfolio Management, LLC
5.14% · 3.86M sh
Vanguard Capital Management, LLC
3.56% · 2.68M sh
UBS Asset Management
3.45% · 2.59M sh
Sumitomo Mitsui Trust Asset Management
3.41% · 2.55M sh
Amova Asset Management
3.40% · 2.55M sh
ARK Investment Management LLC
3.16% · 2.37M sh
AQR Capital Management
2.59% · 1.94M sh
State Street Global Advisors
3.10% · 2.33M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Bill & Melinda Gates Foundation Asset Trust | -- | 21.51% |
| Richard Friesner | Co-Founder, Scientific Advisory Chairman and Director | 1.87% |
| Ramy Farid | Chief Executive Officer | 0.36% |
| Kenneth Lorton | Executive VP, CTO & COO of Software | 0.05% |
| Gary Sender | Independent Director | 0.02% |
| Nancy Thornberry | Independent Director | 0.02% |
| Jeffrey Chodakewitz | Independent Director | 0.02% |
| Michael Lynton | Independent Chairperson | 0.02% |
| Gary Ginsberg | Independent Director | 0.02% |
| Rosana Kapeller-Libermann | Independent Director | 0.02% |
| Arun Oberoi | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Robert Abel | Executive VP, Chief Scientific Officer of Platform and Head of Modeling R&D | Open Market Disposition | -1,678 | $34.00 |
| 2026-11-10 | Robert Abel | Executive VP, Chief Scientific Officer of Platform and Head of Modeling R&D | Derivative Exercise and Sale | -21,927 | $17.00–34.00 |
| 2026-11-10 | Paul Davie | Executive VP, Chief Commercial Officer, Global Head of Software Sales & Marketing | Other Acquisition | +18,400 | -- |
| 2026-11-10 | Paul Davie | Executive VP, Chief Commercial Officer, Global Head of Software Sales & Marketing | Other Derivative Acquisition | +110,600 | $31.52 |
| 2026-11-08 | Yvonne Tran | Corporate Secretary, Chief Legal & People Officer | Derivative Exercise and Sale | -32,000 | $17.00–33.11 |
| 2026-09-16 | Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships | Derivative Exercise and Sale | -31,599 | $4.34–30.00 |
| 2026-07-15 | Richie Jain | Chief Financial Officer | Automatic Disposition | -875 | $15.60 |
| 2026-06-30 | Mannix Aklian | -- | Intent to Sell (Form 144) | -1,136 | $16.68 |
| 2026-06-25 | Richard Friesner | Co-Founder, Scientific Advisory Chairman and Director | Other Acquisition | +679,373 | -- |
| 2026-06-25 | Richard Friesner | Co-Founder, Scientific Advisory Chairman and Director | Other Disposition | -679,373 | -- |
| 2026-06-21 | Michael Lynton | Independent Chairperson | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Michael Lynton | Independent Chairperson | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Gary Ginsberg | Independent Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Gary Ginsberg | Independent Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Gary Sender | Independent Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Gary Sender | Independent Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Arun Oberoi | Independent Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Arun Oberoi | Independent Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Rosana Kapeller-Libermann | Independent Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Rosana Kapeller-Libermann | Independent Director | Other Derivative Acquisition | +13,313 | $15.23 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Schrodinger discussion 0 comments